Spiral Therapeutics Welcomes New Investment, Cementing Its Leadership in Neurotology
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 /PRNewswire/ -- Spiral Therapeutics, Inc. ("Spiral"), a clinical-stage company focused on delivering therapies for inner ear disorders, today announced a new round of financing led by Esperante Ventures and Ferring Ventures SA.
- SOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 /PRNewswire/ -- Spiral Therapeutics, Inc. ("Spiral"), a clinical-stage company focused on delivering therapies for inner ear disorders, today announced a new round of financing led by Esperante Ventures and Ferring Ventures SA.
- As part of this financing, Spiral welcomes the addition of Dean Slagel, Managing Director of Esperante Ventures, to its Board of Directors.
- Last year Spiral completed enrollment of an open label clinical study of SPT-2101 in patients with Meniere's Disease.
- With the recent acquisition of Otonomy assets and our growing therapeutic pipeline, we are positioning Spiral as a forerunner in the field."